Science and Technology Resources

新型亲和试剂的开发。在过去的财政年度，科学和技术资源办公室（OSTR）继续支持一项倡议，即生产高亲和力试剂，作为癌症发展过程中改变的分子通路的分子询问工具。与三家生物技术公司（Beckton Dickinson, Pharmingen， Rockland Immunochemicals和Epitomics）的合作，以最低的成本为CCR研究人员创造了近200种新型亲和试剂，针对数百种CCR感兴趣的关键癌症相关靶点的多克隆和单克隆抗体。这些伙伴关系为CCR和NCI节省了100多万美元。所有由参与CCR的研究人员产生的抗体特性数据都可以通过OSTR和高级生物医学计算中心（ABCC）合作开发的网站提供给相关公司。当抗体被商业化时，每家公司都会在他们的营销材料中使用这些数据。我们与Epitomics的合作是为了生产兔单克隆抗体。已知这些抗体比小鼠单克隆或兔多克隆抗体更稳定，具有更高的亲和力。OSTR与该公司签订了一份合同，以较目录价格大幅降低的成本（5900美元对20000美元）进入其抗体生产管道。与其他合作项目类似，CCR研究人员将被要求对抗体进行表征，并将数据提供给Epitomics进行验证和商业化。OSTR正在通过弗雷德里克国家实验室（FNL）的蛋白质表征实验室，为CCR研究人员在哺乳动物细胞中进行一系列蛋白质相互作用筛选提供支持。OSTR继续评估所有商用平台的基因表达谱和其他高通量基因组技术。为了使CCR研究人员更容易获得最新进展，OSTR与提供基因组和代谢组学分析技术和服务的公司（Affymetrix, NanoString, Agilent, Illumina, GenUs, Qiagen， HMT， Metabolon等）建立了许多安排。这些协议大大降低了CCR研究人员获取这些技术的成本和效率。已经建立了一项补贴计划，为CCR研究者提供补贴，以支持他们获得先进的基因组学、蛋白质组学、代谢组学和生物信息学技术。这种资助机制有助于扩大CCR实验室可用的有限研究资金，并允许我们的研究人员进行原本可能成本过高的实验。许多资助的项目都在顶级期刊上发表了重要论文。最近，OSTR参与了CCR获取下一代测序技术的努力，包括在37号楼建立一个新的NGS核心，供CCR的任何研究人员使用。为了应对CCR对管理和分析大量基因组和蛋白质组学数据的快速增长的需求，OSTR与一些生物信息学公司建立了合作关系。为了显著节省NCI的成本，OSTR代表所有NCI研究人员谈判了各种许可协议，以普及用于微阵列实验、蛋白质组学分析研究和基因组分析（包括下一代测序数据）的生物信息学和统计分析的复杂工具。此外，OSTR还为所有NCI提供了一些用于研究通路和生物关联网络的软件应用程序。OSTR继续评估CCR在生物信息学和生物统计学领域的要求。我们继续与Leidos信息系统计划合作，创建一个专门的CCR生物信息学计划，为CCR研究人员提供支持。这个位于贝塞斯达校区的新项目支持高通量基因组和蛋白质组学数据的分析。

Development of Novel Affinity Reagents. During the past fiscal year, the Office of Science and Technology Resources (OSTR) has continued to support an initiative for generating high affinity reagents to serve as tools for molecular interrogation of pathways that become altered during cancer development. Partnerships with three biotechnology companies (Beckton Dickinson, Pharmingen, Rockland Immunochemicals, and Epitomics) have led to the creation of nearly 200 novel affinity reagents, polyclonal, and monoclonal antibodies against hundreds of key cancer related targets of interest to the CCR at minimal cost to CCR investigators. These partnerships represent savings of more than one million dollars to CCR and the NCI. All of the antibody characterization data generated by participating CCR investigators is made available to the companies involved through a Web site developed in a collaboration between the OSTR and the Advanced Biomedical Computing Center (ABCC). Each company uses this data in their marketing material when the antibodies are released for commercialization. Our partnership with Epitomics is for production of rabbit monoclonal antibodies. These antibodies are known to be much more stable and have higher affinities than mouse monoclonal or rabbit polyclonal antibodies. The OSTR negotiated a contract with the company to access their antibody production pipeline at a significantly reduced cost ($5,900 versus $20,000) from the catalog price. Similar to the other collaborative programs, CCR investigators will be required to characterize the antibodies and make data available to Epitomics for validation and commercialization. The OSTR is supporting a number of protein interaction screens in mammalian cells for CCR investigators through the Laboratory of Protein Characterization at the Frederick National Lab (FNL). The OSTR continues to evaluate all commercially available platforms gene expression profiling and other high throughput genomic technologies. To make the latest advances easily accessible to CCR researchers, the OSTR has established a number of arrangements with companies providing genomic and metabolomic profiling technologies and services (Affymetrix, NanoString, Agilent, Illumina, GenUs, Qiagen, HMT, Metabolon, etc.). These agreements have led to far lower cost and an efficient and easy way for CCR investigators to access these technologies. A subsidy program has been established providing subsidies to support CCR investigator access to advanced genomic, proteomic, metabolomic, and bioinformatic technologies. This funding mechanism has helped to extend the limited research dollars available to CCR laboratories and has permitted our researchers to conduct experiments that might otherwise be cost prohibitive. Many of the funded projects have led to important publications in top tier journals. Most recently, the OSTR has been involved in CCR's efforts to access the next generation sequencing technologies, including the setting up of a new NGS Core in building 37, which is available to any CCR investigator. In response to CCR's rapidly growing need to manage and analyze large sets of genomic and proteomic data, the OSTR has developed several partnerships with bioinformatics companies. At significant cost savings to NCI, OSTR negotiated a variety of license agreements on behalf of all NCI researchers for universal access to sophisticated tools for bioinformatic and statistical analysis of microarray experiments, proteomic profiling studies, and genomic analysis including next generation sequencing data. In addition, the OSTR has made a number of software applications for the investigation of pathways and biological association networks available to all of NCI. The OSTR continues to assess CCR's requirements in the area of bioinformatics and biostatistics. We continue to work with the Leidos Information Systems Program to create a CCR dedicated Bioinformatics Program to provide support to CCR investigators. Support for analysis of high throughput genomic and proteomic data is being made available through this new program, which is located on the Bethesda campus.